Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.
“Neptazane represents an alternative to eye drops when IOP is not effectively controlled or patient compliance becomes an issue. And Neptazane is a brand name the eye care community knows and trusts”
Neptazane is an important oral treatment option for physicians and patients who require effective reduction of intraocular pressure (IOP).
High IOP can lead to glaucoma if left untreated. According to Glaucoma Research Foundation, it is estimated that over 4 million Americans have glaucoma but only half of those know they have it and about 2% of the population ages 40-50 and 8% over 70 have elevated IOP.
"Neptazane represents an alternative to eye drops when IOP is not effectively controlled or patient compliance becomes an issue. And Neptazane is a brand name the eye care community knows and trusts" says David Cobb, Vice President of Ophthalmics for Fera.
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status